The Parkinson's-Reversing Breakthrough

Alternative Treatment for Parkinsons

Get Instant Access

1. Liang E, Wang X, Khor S, Hsu A. Comparison of pharmacokinetics of levodopa and car-bidopa between IPX054 and Sinemet and Sinemet CR tablets in healthy subjects under fasting conditions. Mov Disord 2006; 21(suppl 13):S125.

2. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease—long-term experience. Acta Neurol Scand 2001; 104(6):343-348.

3. Isaias I, Lombardy P, Zibetti M, et al. Quality of life changes during Duodopa infusion in Parkinson's disease. Neurology 2006; 66(suppl 2):A294.


5. Parkinson Study Group. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol 2006; 63:210-216.

6. Pahwa R, Factor S, Elmer L. Ropinirole 24 hour prolonged release reduces awake time spent "off " in patients with Parkinson's disease not optimally controlled with l-dopa. Neurology 2006; 66(suppl 2):A292.

7. Metman LV, Gillespie M, Farmer C, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 2001; 24:163-169.

8. Bianchine J, Poole K, Woltering F. Efficacy and dose response of the novel transdermally applied dopamine agonist rotigotine CDS in early Parkinson's disease. Neurology 2002; 58(suppl 3):A162-A163.

9. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005; 65:S3-S5.

10. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003; 60:1721-1728.

11. Poewe W, Luessi F. Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology 2005; 65:S11-S14.

12. Watts RL, Wendt J, Nausieda PL, Boroojerdi B, Poole KH, Sommerville KW. Efficacy, safety and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial. Mov Disord 2004; 19(suppl 9):S258.

13. Lewitt P, Nausieda P, Chang F, et al. Rotigotine transdermal system in a multicenter trial of Parkinson's disease as adjunctive therapy to levodopa. Neurology 2006; 66(suppl 2):A184.

14. Benes H. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome. Sleep Med 2006; 7:31-35.

15. Woitalla D, Muller T, Benz S, Horowski R, Przuntek H. Transdermal lisuride delivery in the treatment of Parkinson's disease. J Neural Transm 2004; 6(68):89-95.

16. Dimitrova T, Bara-Jimenez W, Thomas M, Bibbiani F, Zhang X. Continous dopaminergic stimulation with lisuride TTS (patch) in moderately advanced Parkinsonian patients. Neurology 2006; 66(suppl 2):A185.

17. Castro-Caldas A, Delwaide P, Jost W, et al. The Parkinson-Control study: A 1-year randomized, double-blind trial comparing piribedil (150mg/day) with bromocriptine (25mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord 2006; 21:500-509.

18. Suwantamee J, Nidhinandana S, Srisuwananukorn S, et al. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study. J Med Assoc Thai 2004; 87:1293-1300.

19. Evidente VG, Esteban RP, Domingo FM, Carbajal LO, Parazo MA. Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience. Parkinsonism Relat Disord 2003; 10:117-121.

20. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. Mov Disord 2003; 18:418-425.

21. Simon N, Micallef J, Reynier JC, et al. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacoki-netic/pharmacodynamic, randomized, double-blind study. Mov Disord 2005; 20:803-809.


23. Marzo A, Dal Bo L, Monti NC, et al. Pharmacokinetics and pharmacodynamics of safi-namide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 2004; 50:77-85.

24. Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004; 63:746-748.

25. Pearce RK, Smith LA, Jackson MJ, Banerji T, Scheel-Kruger J, Jenner P. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Mov Disord 2002; 17:877-886.

26. Frackiewicz EJ, Jhee SS, Shiovitz TM, et al. Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. Ann Pharmacother 2002; 36:225-230.

27. Jenner P. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 2003; 61(suppl 6):S32-S38.

28. Harper LK, Beckett SR, Marsden CA, McCreary AC, Alexander SP. Effects of the A(2A) adenosine receptor antagonist KW6002 in the nucleus accumbens in vitro and in vivo. Pharmacol Biochem Behav 2006; 83:114-121.

29. Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 2003; 61:S107-S111.

30. Kase H, Aoyama S, Ichimura M, et al. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 2003; 61:S97-S100.

31. Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003; 61:297-303.

32. Harris CA, Deshmukh M, Tsui-Pierchala B, Maroney AC, Johnson EM Jr., Ylikoski J. Inhibition of the c-Jun N-terminal kinase signaling pathway by the mixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons. J Neurosci 2002; 22:103-113.

33. Maroney AC, Glicksman MA, Basma AN, et al. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci 1998; 18:104-111.



36. Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology 2006; 66:408-410.

37. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 2005; 57:298-302.

38. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59: 459-466.

39. Ericson C, Georgievska B, Lundberg C. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Eur J Neurosci 2005; 22:2755-2764.

40. Sajadi A, Bensadoun JC, Schneider BL, Lo Bianco C, Aebischer P. Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. Neurobiol Dis 2006; 22:119-129.

41. Poulter MO, Payne KB, Steiner JP. Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 2004; 128:1-6.

42. Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999;157:142-149.

43. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of crea-tine and minocycline in early Parkinson disease. Neurology 2006; 66:664-671.

44. Zemke D, Majid A. The potential of minocycline for neuroprotection in human neurologic disease. Clin Neuropharmacol 2004; 27:293-298.

45. Thomas M, Le WD. Minocycline: neuroprotective mechanisms in Parkinson's disease. Curr Pharm Des 2004; 10:679-686.

46. Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002; 22:1763-1771.

47. Schapira AH, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. Journal of Neurochemistry 1990; 55:2142-2145.

48. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AH. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 1992; 32:782-788.

49. Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 1997; 42:261-264.

50. Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 1998; 783:109-114.

51. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59:1541-1550.

52. Muller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 2003; 341:201-204.

53. Bartoszyk GD, Van Amsterdam C, Greiner HE, Rautenberg W, Russ H, Seyfried CA. Sari-zotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm 2004; 111:113-126.

54. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001; 57:1829-1834.

55. Olanow CW, Damier P, Goetz CG, et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004;27:58-62.


57. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004; 101:9861-9866.

58. Tousi B, Subramanian T. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease. Parkinsonism Relat Disord 2005; 11:333-334.

59. Lyons KE, Pahwa R. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 2006; 29:148-153.


61. Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003; 18:872-883.


Was this article helpful?

0 0

Post a comment